cbdMD, Inc.
YCBD Healthcare Drug Manufacturers Specialty & Generic
cbdMD, Inc.’s revenue for fiscal 2025 (year ended September 2025) was $19.2 million, down 1.50% from fiscal 2024. In the quarter to June 2026, revenue grew 20.6%, EPS grew 47.6% and free cash flow grew 34.8%, each against the same quarter a year earlier.
Follow YCBD
cbdMD, Inc. (YCBD) P/E ratio
As of 16 October 2026, cbdMD, Inc. (YCBD) trades at a P/E ratio of 41.2×. Over the past ten years it has ranged from 0.0× (June 2026) to 660× (September 2018); the current reading is higher than 91% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of 19.2× and above the Healthcare sector median of 23.0×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 3.8× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 78.8× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 35 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| SNOA Sonoma Pharmaceuticals, Inc. compare | n/m |
| APUS Apimeds Pharmaceuticals US, Inc. compare | n/m |
| PRFX PainReform Ltd. compare | n/m |
| BTAIQ BioXcel Therapeutics, Inc. compare | n/m |
| RDHL Redhill Biopharma Ltd. compare | n/m |
| INM InMed Pharmaceuticals Inc. compare | n/m |
| YCBD cbdMD, Inc. | 41.2× |
| GELS Gelteq Limited compare | — |
| AKAN Akanda Corp. compare | — |
| Drug Manufacturers Specialty & Generic industry median | 19.2× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)